EKSTERMED
Dead / Abandoned — Abandoned — no statement of use filed (as of 27 May 2024)
What this means for you
This application is over — abandoned 27 May 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90157600
- Mark type
- Design + words
- Filed
- 03 Sept 2020
- Published for opposition
- 23 Feb 2021
- Abandoned
- 27 May 2024
- Attorney of record
- Bret E. Field
Goods and services
- Class 003 — Cosmetics and cleaning preparations: Cosmetics; cosmetic preparations; adhesives for cosmetic purposes; cosmetic masks; non-medicated soaps for personal use; perfumery; essential oils; hair lotions
- Class 005 — Pharmaceuticals: Pharmaceuticals for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; pharmaceutical preparations, compositions, creams and lotions for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations, namely, transdermal gel formulations, transdermal cream formulations, oral mucous formulations, transdermal patches, dressings and medical adhesive tapes for use in the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions
Owner
- Teikoku Pharma USA, Inc., San Jose, CA, US
- Teikoku Pharma USA, Inc., San Jose, CA, US
Prosecution history
- 12 Jul 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 27 May 2024 — ABANDONMENT - NO USE STATEMENT FILED
- 19 Oct 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Oct 2023 — SOU EXTENSION 5 GRANTED
- 16 Oct 2023 — SOU EXTENSION 5 FILED
- 16 Oct 2023 — SOU TEAS EXTENSION RECEIVED
- 19 Apr 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Apr 2023 — SOU EXTENSION 4 GRANTED
- 17 Apr 2023 — SOU EXTENSION 4 FILED
- 17 Apr 2023 — SOU TEAS EXTENSION RECEIVED
- 19 Oct 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Oct 2022 — SOU EXTENSION 3 GRANTED
- 17 Oct 2022 — SOU EXTENSION 3 FILED
- 17 Oct 2022 — SOU TEAS EXTENSION RECEIVED
- 19 Apr 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED